Dear Reader :

This month’s newsletter, co-developed by the IPA and Citeline, highlights all the big talking points at the BIO International Convention in San Diego and the return of momentum in the clinical trials arena.

We tell you why Amgen’s CEO had some tough words on the Inflation Reduction Act, labelling it the ‘Innovation Reduction Act’ at BIO and also spotlight key trial trends now that the pandemic-related turmoil has abated.

There’s also a fascinating piece on advances in minimally invasive bioelectronics for mental health.

Anju Ghangurde - Executive Editor (Asia Pacific), Scrip/Pink Sheet
Dr. Shridhar Narayanan - Senior Technical Advisor - Innovation, IPA

Perspective From Industry Leaders
BIO Notebook: Amgen CEO Blasts IRA, Novo Nordisk Stays Cautious On BD, And More ‘That’s A Much Broader Statement’: Hikma Grilled In Amarin Vascepa Skinny-Label Appeal
BIO Notebook: Amgen CEO Blasts IRA, Novo Nordisk Stays Cautious On BD, And More ‘That’s A Much Broader Statement’: Hikma Grilled In Amarin Vascepa Skinny-Label Appeal

Insights from Day Three of the BIO International Convention in San Diego include Amgen CEO Bob Bradway...

Hikma may have succeeded in dismissing Amarin’s induced infringement claim against the firm over Hikma’s skinny...

Licensing & Collaboration Agreements
BIO Roundup: Deal-Making Tips And Tricks BioBytes: AI-Related Deals In Q1 2024
BIO Roundup: Deal-Making Tips And Tricks BioBytes: AI-Related Deals In Q1 2024

Key insights from the recent the BIO International Convention in San Diego, US.

BioBytes presents an overview of AI-related deals in Q1 2024. This is the first in a recurring series of quarterly deal...

Next Gen R&D
ADDF Leaders Discuss Future Strategies In Alzheimer’s Research And Crucial Role Of Diagnostic Markers ‘Mental Health, Beyond Medication’: Motif Targets Depression With Minimally Invasive DOT
ADDF Leaders Discuss Future Strategies In Alzheimer’s Research And Crucial Role Of Diagnostic Markers ‘Mental Health, Beyond Medication’: Motif Targets Depression With Minimally Invasive DOT

Medtech Insight talked to two leaders at the Alzheimer’s Drug Discovery Foundation about current therapies...

Motif’s “pea-sized” Digitally programmable Over-brain Therapeutic (DOT) requires 20 minutes to implant...

Clinical Trials
What Pandemic? Clinical Trials Shake The COVID-19 Dust Off Their Feet Jazz’s Suvecaltamide Fails In Tremor Trial, But Parkinson’s Study Continues
What Pandemic? Clinical Trials Shake The COVID-19 Dust Off Their Feet Jazz’s Suvecaltamide Fails In Tremor Trial, But Parkinson’s Study Continues

Industry-sponsored clinical trial activity has returned to pre-pandemic trends now that the turmoil of COVID-19...

A Phase IIb trial evaluating suvecaltamide failed to show a statistically significant benefit versus placebo on...

Citeline Contact

Poornachandra Tejasvi .K,
Senior Director - Emerging Markets, India
Mobile: +91 9945273146
Email: poornachandra.tejasvi@citeline.com
Client Services: clientservices@citeline.com

alt_text   alt_text
IPA Contact

Name: Hari Pranav K
Email: haripranav.k@ipa-india.org